UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 48

Sortiert nach

Interferon gene therapy with nadofaragene firadenovec for bladder cancer: from bench to approval

Frontiers in immunology, 2023-08, Vol.14, p.1260498

2023

Volltextzugriff (PDF)

Nephron Progenitor But Not Stromal Progenitor Cells Give Rise to Wilms Tumors in Mouse Models with β-Catenin Activation or Wt1 Ablation and Igf2 Upregulation

Neoplasia (New York, N.Y.), 2016-02, Vol.18 (2), p.71-81

2016

Volltextzugriff (PDF)

Epidermal transglutaminase (TGase 3) is required for proper hair development, but not the formation of the epidermal barrier

PloS one, 2012-04, Vol.7 (4), p.e34252-e34252

2012

Volltextzugriff (PDF)

Compound Genetic Ablation of Nidogen 1 and 2 Causes Basement Membrane Defects and Perinatal Lethality in Mice

Molecular and Cellular Biology, 2005-08, Vol.25 (15), p.6846-6856

2005

Volltextzugriff (PDF)

Nidogens-Extracellular matrix linker molecules

Microscopy research and technique, 2008-05, Vol.71 (5), p.387-395

2008

Volltextzugriff (PDF)

Inhibition of urothelial carcinoma through targeted type I interferon-mediated immune activation

Oncoimmunology, 2019-05, Vol.8 (5), p.e1577125-e1577125

2019

Volltextzugriff (PDF)

Lentiviral interferon: A novel method for gene therapy in bladder cancer

Molecular therapy. Oncolytics, 2022-09, Vol.26, p.141-157

2022

Volltextzugriff (PDF)

MP65-06 NOVEL COMBINATION THERAPY USING INTERFERON GENE THERAPY AND GEMCITABINE IN MURINE BLADDER CANCER CELL LINES

The Journal of urology, 2024-05, Vol.211 (5S)

2024

Volltextzugriff (PDF)

MP65-05 SINGLE-CELL RNA SEQUENCING IDENTIFIES CHANGES IN TUMOR MICROENVIRONMENT INDUCED BY INTERFERON α GENE THERAPY IN MURINE BLADDER CANCER MODEL

The Journal of urology, 2024-05, Vol.211 (5S)

2024

Volltextzugriff (PDF)

PD25-06 COMBINATION TREATMENT WITH INTRAVESICAL INTERFERON GENE THERAPY AND PAN-ERBB RECEPTOR FAMILY BLOCKER IMPROVES SURVIVAL IN MICE WITH BLADDER CANCER

The Journal of urology, 2023-04, Vol.209 (Supplement 4)

2023

Volltextzugriff (PDF)

PD12-03 INTERFERON α GENE THERAPY ALTERS TUMOR METABOLISM IN BLADDER CANCER

The Journal of urology, 2022-05, Vol.207 (Supplement 5)

2022

Volltextzugriff (PDF)

PD12-02 PATIENT-DERIVED BLADDER TUMOR ORGANOIDS FOR INDIVIDUALIZED PRECLINICAL CHARACTERIZATION OF NADOFARAGENE FIRADENEOVEC INTERFERON GENE THERAPY

The Journal of urology, 2022-05, Vol.207 (Supplement 5)

2022

Volltextzugriff (PDF)

The current status of gene therapy in bladder cancer

Expert review of anticancer therapy, 2023-05, Vol.23 (5), p.531-543

2023

Volltextzugriff (PDF)

SINGLE-CELL RNA SEQUENCING ANALYSIS IDENTIFIES CHANGES IN TUMOR MICROENVIRONMENT INDUCED BY INTERFERON α GENE THERAPY IN A MURINE MODEL OF BLADDER CANCER

Urologic oncology, 2024-03, Vol.42, p.S51-S51

2024

Volltextzugriff (PDF)

NOVEL COMBINATION THERAPY USING INTERFERON GENE THERAPY AND GEMCITABINE IN MURINE BLADDER CANCER CELL LINES

Urologic oncology, 2024-03, Vol.42, p.S47-S48

2024

Volltextzugriff (PDF)

Bladder tumor metabolic alterations in response to IFNα gene therapy

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.468-468

2021

Volltextzugriff (PDF)

MP59-01 URINE MICRORNAS AS LIQUID BIOPSY ASSAY FOR PREDICTING RESPONSE TO INTRAVESICAL BCG THERAPY

The Journal of urology, 2022-05, Vol.207 (Supplement 5)

2022

Volltextzugriff (PDF)

Pim kinase isoforms: devils defending cancer cells from therapeutic and immune attacks

Apoptosis (London), 2016-11, Vol.21 (11), p.1203-1213

2016

Volltextzugriff (PDF)

MP16-07 URINARY MINIMAL RESIDUAL DISEASE DETECTION PREDICTS RECURRENCE IN BCG-UNRESPONSIVE NIMBC AND QUANTIFIES MOLECULAR RESPONSE TO NADOFARAGENE FIRADENOVEC

The Journal of urology, 2024-05, Vol.211 (5S)

2024

Volltextzugriff (PDF)

Characterization of FOXF1 as a novel regulator of nodal metastasis in bladder cancer

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.480-480

2021

Volltextzugriff (PDF)

MP54-05 EVALUATING INTRAVESICAL NADOFARAGENE FIRADENOVEC AND IMMUNE CHECKPOINT BLOCKADE COMBINATION THERAPY IN BCG-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER: EVIDENCE FROM A PHASE 3 TRIAL

The Journal of urology, 2022-05, Vol.207 (Supplement 5)

2022

Volltextzugriff (PDF)

β-Catenin Activation in a Novel Liver Progenitor Cell Type Is Sufficient to Cause Hepatocellular Carcinoma and Hepatoblastoma

Cancer research (Chicago, Ill.), 2014-08, Vol.74 (16), p.4515-4525

2014

Volltextzugriff (PDF)

PD37-02 FOXF1 IS A NOVEL REGULATOR OF NODAL METASTASIS IN BLADDER CANCER

The Journal of urology, 2021-09, Vol.206 (Supplement 3)

2021

Volltextzugriff (PDF)

FOXF1: A NOVEL REGULATOR OF METASTASIS IN UROTHELIAL CARCINOMA OF THE BLADDER

Urologic oncology, 2024-03, Vol.42, p.S27-S27

2024

Volltextzugriff (PDF)

Immune modulation by combination type I interferon and checkpoint blockade therapy in murine urothelial carcinoma

The Journal of immunology (1950), 2018-05, Vol.200 (1_Supplement), p.122-122.12

2018

Volltextzugriff (PDF)

1 – 25 von 48

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(48)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(48)

Sprache

Englisch
(48)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Interferon gene therapy with nadofaragene firadenovec for bladder cancer: from bench to approval

Nephron Progenitor But Not Stromal Progenitor Cells Give Rise to Wilms Tumors in Mouse Models with β-Catenin Activation or Wt1 Ablation and Igf2 Upregulation

Epidermal transglutaminase (TGase 3) is required for proper hair development, but not the formation of the epidermal barrier

Compound Genetic Ablation of Nidogen 1 and 2 Causes Basement Membrane Defects and Perinatal Lethality in Mice

Nidogens-Extracellular matrix linker molecules

Inhibition of urothelial carcinoma through targeted type I interferon-mediated immune activation

Lentiviral interferon: A novel method for gene therapy in bladder cancer

MP65-06 NOVEL COMBINATION THERAPY USING INTERFERON GENE THERAPY AND GEMCITABINE IN MURINE BLADDER CANCER CELL LINES

MP65-05 SINGLE-CELL RNA SEQUENCING IDENTIFIES CHANGES IN TUMOR MICROENVIRONMENT INDUCED BY INTERFERON α GENE THERAPY IN MURINE BLADDER CANCER MODEL

PD25-06 COMBINATION TREATMENT WITH INTRAVESICAL INTERFERON GENE THERAPY AND PAN-ERBB RECEPTOR FAMILY BLOCKER IMPROVES SURVIVAL IN MICE WITH BLADDER CANCER

PD12-03 INTERFERON α GENE THERAPY ALTERS TUMOR METABOLISM IN BLADDER CANCER

PD12-02 PATIENT-DERIVED BLADDER TUMOR ORGANOIDS FOR INDIVIDUALIZED PRECLINICAL CHARACTERIZATION OF NADOFARAGENE FIRADENEOVEC INTERFERON GENE THERAPY

The current status of gene therapy in bladder cancer

SINGLE-CELL RNA SEQUENCING ANALYSIS IDENTIFIES CHANGES IN TUMOR MICROENVIRONMENT INDUCED BY INTERFERON α GENE THERAPY IN A MURINE MODEL OF BLADDER CANCER

NOVEL COMBINATION THERAPY USING INTERFERON GENE THERAPY AND GEMCITABINE IN MURINE BLADDER CANCER CELL LINES

Bladder tumor metabolic alterations in response to IFNα gene therapy

MP59-01 URINE MICRORNAS AS LIQUID BIOPSY ASSAY FOR PREDICTING RESPONSE TO INTRAVESICAL BCG THERAPY

Pim kinase isoforms: devils defending cancer cells from therapeutic and immune attacks

MP16-07 URINARY MINIMAL RESIDUAL DISEASE DETECTION PREDICTS RECURRENCE IN BCG-UNRESPONSIVE NIMBC AND QUANTIFIES MOLECULAR RESPONSE TO NADOFARAGENE FIRADENOVEC

Characterization of FOXF1 as a novel regulator of nodal metastasis in bladder cancer

MP54-05 EVALUATING INTRAVESICAL NADOFARAGENE FIRADENOVEC AND IMMUNE CHECKPOINT BLOCKADE COMBINATION THERAPY IN BCG-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER: EVIDENCE FROM A PHASE 3 TRIAL

β-Catenin Activation in a Novel Liver Progenitor Cell Type Is Sufficient to Cause Hepatocellular Carcinoma and Hepatoblastoma

PD37-02 FOXF1 IS A NOVEL REGULATOR OF NODAL METASTASIS IN BLADDER CANCER

FOXF1: A NOVEL REGULATOR OF METASTASIS IN UROTHELIAL CARCINOMA OF THE BLADDER

Immune modulation by combination type I interferon and checkpoint blockade therapy in murine urothelial carcinoma

Suchergebnisse filtern